Kornimate/medical-research-clean huggingface dataset:
immediate and short-term effects of low-level laser

Conditions: Fatigue; Muscle Injury

Summary: athletes experience an exhaustive routine of training, associated with the reduced time of rest, facilitates the appearance of muscle fatigue, which increases the risk of muscle injuries, especially during the execution of the jump. low level lasertherapy is a technique that has been increasingly improved due to the physiological effects it provides in the muscle recovery process. however, there is still a lack of studies focused on the use of this technique in functional improvement, especially in jumping sports. objectives: to evaluate the immediate and short-term effects of low-level laser on the functional performance of lower limbs of jumping athletes and to evaluate the short-term effects of low-level laser on the activation of the gluteus medius and quadriceps muscles. methods: this is a brief, double-blind, randomized, placebo-controlled clinical trial. will be recruited 24 handball and volleyball players aged between 18 to 35 years. the primary outcome of our study is functional performance (modified hop test and modified sebt), and as a secondary outcome (level of electromyographic activity). after the baseline assessments, the athletes will be randomized and allocated into two groups: intervention group (ig, n=12) and control group (cg, n=12) and submitted to a fatigue protocol, followed by laser therapy or placebo.


Eligibility criteria:
inclusion criteria: * handball and volleyball athletes; * age between 18 and 35 years; * both sexes; * athletes who maintain a training routine for their sport, at least twice a week exclusion criteria: * history of acute injury to the lower limbs (ll) in the last 2 months; * occurrence of pain and injury during the study; * any change in physical activity routine during the week of assessments.
anesthesia of endolaryngeal laser surgery and perioperative side effects

Conditions: Anesthesia

Summary: investigators analyze the anesthesia of the endolaryngeal laser surgery in patients with smoking with or without monitoring of depth of anesthesia (bispectral index)

all participants are informed about the investigation and are signed the informed consent before anesthesia. the study takes place at the department of otorhinolaryngology, university of pecs, hungary. between june 2021 and may 2022 asa i or ii patients aged 18-65 years, scheduled for elective endolaryngeal laser surgery with tci (target-controlled infusion, propofol). exclusion criteria are epilepsy, psychiatric illness, cerebrovascular or congenital neuromuscular disease. participants are randomized to two anesthetic groups, anesthesia with or without bispectral index monitoring.

Eligibility criteria:
inclusion criteria: * endolaryngeal laser surgery with target-controlled anesthesia exclusion criteria: * epilepsy, psychiatric illness, cerebrovascular or congenital neuromuscular disease

Keywords: laser, anesthesia, bispectral index, postoperative delirium
multidisciplinary digital therapeutics of patellofemoral pain syndrome versus usual care

Conditions: Patellofemoral Pain Syndrome

Summary: this randomized controlled pilot study will be evaluating an app, mort-pfps app (eth-01k), owned by everex, inc., to examine safety and effectiveness in individuals with patellofemoral pain syndrome.

this randomized controlled pilot study will enroll 40 participants, where half will be randomly assigned to the app, mort-pfps (n = 20), and half will be assigned to treatment as usual (tau) (n = 20), to examine safety and effectiveness in individuals with patellofemoral pain syndrome. all subjects will be followed up in the study for a total of 12 weeks, 8-week courses of treatment with additional 4-week observation. the app provides multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.

Eligibility criteria:
inclusion criteria: * male or female ≥ 19 and \<50 years of age * patients who have a history of anterior knee pain in one or both knees, persisting for longer than 3months but not longer than 2 years * patients who have pain provoked by squatting * patients who have pain provoked by 2 or more following activities 1. long sitting 2. cycling 3. running 4. going up or down stairs 5. kneeling 6. compression of the patella 7. palpation of the patellar facets * patients who signed a written informed consent form exclusion criteria: * patients with osteoarthritis which scored 2 or higher grade of the kellgren-lawrence scale * patients who have a history of knee pathologies or injuries (fracture, tendon injury, cartilage injury, or patella dislocation) * patients who had previous knee surgeries * patients who have patellar tendinopathy * patients who have osgood-schlatter disease, or other defined pathological conditions of the knee * patients who are pregnant or breastfeeding * patients who are using anti-inflammatory medication * patients with known substance/alcohol use disorders * patients with known somatic symptom and related disorders * patients who are not able to participate in an exercise or strengthening program
using smart phone technology to support prep uptake and adherence

Conditions: HIV Prevention; PrEP; Adherence, Medication

Summary: this is a single arm pilot study of a new smartphone app to support adherence to prep medication for hiv prevention in public clinics in virginia.

testing the impact of a smart phone application's impact on prep uptake and adherence. the app features daily medication reminders, daily mood and stress evaluations, a community message board for social support, and patient-provider secure, hipaa compliant private messaging between patients and clinic providers. participants will be recruited from vdh clinics. we will evaluate the adherence and uptake rates of prep among study participants. usage data will be collected from the application, and from participant surveys at 30 day, 3 month, and 6 month study timepoints. surveys will include questionnaires on medication adherence, empathy of providers, experiences with the app, stigma and disclosure attitudes, and social support, along with mental health screening. the study will be analyzed as a prospective one arm study by comparing baseline to 3m and 6m surveys, along with examining and characterizing app usage across time.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * one or considering being on prep for hiv prevention * patient at a vdh or vdh funded clinic * ability to read at a 5th grade reading level exclusion criteria: * hiv positive individuals * persons under the age of 18

Keywords: hiv prevention adherence uptake
combination chemotherapy in treating young adult patients with acute lymphoblastic leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) together with steroid therapy may kill more cancer cells. purpose: this clinical trial is studying the side effects of combination chemotherapy in treating young adult patients with acute lymphoblastic leukemia.

objectives: * to determine the feasibility of combination chemotherapy in young adult patients with acute lymphoid leukemia. * to determine the complete response rate at the end of induction therapy in these patients. * to determine the overall survival of patients treated with these regimens. * to determine the disease-free survival of patients treated with these regimens. * to determine the event-free survival of patients treated with these regimens. * to determine toxicity of these regimens. * to determine compliance related to dose intensity. outline: * steroids prephase therapy: all patients receive steroids (i.e., prednisone or methylprednisolone) and methotrexate. * induction therapy (induction ia followed by ib): patients receive induction ia comprising vincristine, daunorubicin hydrochloride, asparaginase, and prednisone. they then receive induction ib comprising cyclophosphamide, mercaptopurine, and cytarabine. patients who achieve hematological remission proceed to consolidation therapy. * consolidation therapy: patients receive consolidation therapy according to risk group. * standard-risk patients: patients receive high-dose methotrexate and mercaptopurine. * high-risk patients: patients receive consolidation therapy in 3 steps. * step 1: patients receive dexamethasone, vincristine, methotrexate, cytarabine, and asparaginase. * step 2: patients receive dexamethasone, vindesine, methotrexate, ifosfamide, asparaginase, and daunorubicin hydrochloride. * step 3: patients receive dexamethasone, cytarabine, and asparaginase. after completion of consolidation therapy, patients proceed to reinduction therapy. * reinduction therapy (reinduction iia followed by iib): patients receive reinduction iia comprising vincristine, doxorubicin hydrochloride, asparaginase, and dexamethasone. patients then receive reinduction iib comprising cyclophosphamide, thioguanine, and cytarabine.

Eligibility criteria:
disease characteristics: * diagnosis of acute lymphoid leukemia, meeting any of the following criteria: * non-mature b-cell disease * non-philadelphia chromosome positive disease * t -cell or b-cell phenotype patient characteristics: * not specified prior concurrent therapy: * prior pretreatment with antiblastic chemotherapy allowed

Keywords: b-cell adult acute lymphoblastic leukemia recurrent adult acute lymphoblastic leukemia t-cell adult acute lymphoblastic leukemia untreated adult acute lymphoblastic leukemia
effects of immersive virtual reality traning on an eye-hand coordination and time reaction

Conditions: Virtual Reality; Coordination Impairment

Summary: virtual reality (vr) is a three-dimensional image, which is created by means of computer programs. in most educational communities vr has been used as an opportunity to support many students. vr allows the user to observe the world generated for their own needs as the real world and experience impressions that are not available in real life. it was decided to examine how immersive vr-game will affect the eye-hand coordination on music school students. the experimental group received a five-day training sessions using immersive vr game "beat saber", while control group was inactive comparator.

eye-hand coordination can be defined as the ability to perform activities that require the simultaneous use of eyes and hands. eye-hand coordination supports our daily activities, interactions with objects and people, and is critical to understanding how the brain creates internal models of the space and generates movement within it (2). the eye-hand coordination represents the integration of visual information, perceptual stimuli and motor decisions in order to perform a specific task. along with the development of technology, opportunities for stimulation of eye-hand coordination with the use of technical novelties have appeared. virtual reality (vr) is a three-dimensional image, which is created by means of computer programs. it has become one of the technologies that offer many possibilities of application and use of its various aspects that can bring great benefits in the real world. in most educational communities vr has been used as an opportunity to support many students. vr allows the user to observe the world generated for their own needs as the real world and experience impressions that are not available in real life. it can be assumed that vr can help trainers or teachers, especially music teachers, by interacting through movement, realization and graphic images, to develop and shape skills such as eye to hand coordination. the use of virtual reality gives a wide range of possibilities for training, so it was decided to examine how it will affect the coordination of the eye-hand response in music school students. the aim of the research was to evaluate the eye-hand coordination of music school students undergoing training sessions in the musical game "beat saber" conducted in immersive virtual reality.

Eligibility criteria:
inclusion criteria: * acceptance to participate in the research, * age 14-24 exclusion criteria: * diagnosed neurological diseases, * fear of restricted vision or putting on goggles, * diagnosed musculoskeletal diseases, * injuries to the musculoskeletal system, * regular sports activities during the week.

Keywords: virtual reality vr eye-hand coordination exergame energy expenditure
anti-vegf instead of intraoperative fan-shaped photocoagulation in brvo combined with vitreous hemorrhage

Conditions: Anti-VEGF; Branch Retinal Vein Occlusion; Vitrectomy

Summary: to evaluate the efficacy and safety of anti-vegf instead of intraoperative fan-shaped photocoagulation in brvo combined with vitreous hemorrhage.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old; 2. brvo is diagnosed 3. vitreous hemorrhage 4. vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure) exclusion criteria: 1. brvo combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein ) 2. brvo combined with retinal detachment 3. retinal veins are completely whitened 4. iris neovascularization or neovascular glaucoma 5. combined glaucoma 6. combined with other retinopathy 7. received anti-vegf treatment within 3 months before surgery
relation between muscle strength with exercise capacity and dyspnea in ltx

Conditions: Lung Transplantation; Pulmonary Rehabilitation

Summary: severe exercise intolerance and shortness of breath are present in lung transplant candidates. clinical features that reveal these symptoms in terminal period lung patients vary and are unclear. the effect of peripheral muscle strength on exercise capacity and dyspnea will be examined in our study.

yedikule chest diseases patients who have been accepted to participate in the pre-operative rehabilitation program at the pulmonary rehabilitation unit will be included in the study. a 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the pulmonary rehabilitation unit. the tests will be carried out at the beginning and end of rehabilitation. at each testing session, the tests will be performed by the same physiotherapist. the correlations of the test data with each other will be analyzed.

Eligibility criteria:
inclusion criteria: * have a diagnosis of terminally severe lung disease, * being listed for lung transplantation, * medically stable, * had no orthopedic or cardiac problems that would prevent them from exercising * had no transfer problem to the pulmonary rehabilitation center. exclusion criteria: * dont except to participate the study * incompatibility with exhaust * not completing the program

Keywords: rehabilitation exercise maximal inspiratory pressure walk test muscle strength dyspnea lung transplantation
intravenous fluid therapy in hospitals

Conditions: Knowledge Level; Intravenous Fluid Therapy

Summary: the administration of intravenous fluids plays a crucial role in critically ill patients to support optimal management and ensure patient safety. knowledge and conceptual frameworks will influence a clinician's accuracy in providing intravenous fluid therapy to patients. accurate administration of fluid therapy to patients will reduce unwanted side effects and decrease the overall treatment costs during hospitalization. various considerations in administering intravenous fluid therapy are influenced by a clinician's level of knowledge. in indonesia, doctors working in hospitals may have different levels of education and professional status. however, it is currently unclear whether these professional differences among doctors influence their knowledge in administering fluids to patients.


Eligibility criteria:
inclusion criteria: * all anesthesiologist residencies and are willing to complete the questionnaire. * all anesthesia specialists and subspecialists and are willing to complete the questionnaire until finished. exclusion criteria: * all doctors who are unwilling and do not complete the survey questionnaire.
clinical of chocolate balloon dilatation versus plain balloon dilatation to treat arteriosclerosis occlusive disease of lower extremity

Conditions: Atherosclerosis; Ischemia

Summary: this is a prospective randomized controlled study to evaluate the difference of safety，effectiveness between chocolate balloon and plain balloon dilatation in treatment of infrapopliteal artery lesions.

prospective randomized controlled study to evaluate the difference of safety，effectiveness between chocolate balloon and plain balloon dilatation in treatment of infrapopliteal artery lesions. patients with femoral-popliteal artery lesions in our department were randomly assigned to the chocolate balloon group and plain balloon dilatation group. compare the ischemic improvement rate (limb salvage rate, postoperative patency rate) and the complications rate of two different treatments.

Eligibility criteria:
inclusion criteria： 1.all patients signed an informed consent form; 2.digital subtraction angiography (dsa) revealed femoropopliteal artery stenosis above 70% or occlusion resulting in claudication (rutherford clinical category-becker class ii-iii2-3) or critical limb ischemia (cli) (rutherford clinical category 4-5-becker class iv-v) 3.with unobstructed vascular inflow; 4.with at least a vessel runoff; 5. good compliance and regular follow-up. exclusion criteria: 1. acute or subacute lower limb ischemia caused by acute intraluminal thrombus within the target lesion.; 2. severe calcified lesions （grade 4 in the pacss scale）; 3. in-stent restenosis lesion or surgical arterial bypass grafting; 4. severe renal insufficiency: creatinine level greater than 2.5 mg/dl; 5. platelet count below 100,000/μl or with antiplatelet / anticoagulation contraindications; 6. immunologic diseases or malignant diseases; 7. ongoing active infection; 8. decompensated congestive heart failure or acute coronary syndrome; 9. refuse to sign the informed consent unwillingness to comply with follow-up suggestions.

Keywords: chocolate balloon infrapopliteal artery
a study to confirm recurrent or persistent cushing's syndrome in patients with signs or symptoms of hypercortisolemia

Conditions: Cushing's Syndrome

Summary: this is an observational study to confirm the presence of recurrent or persistent endogenous cushing's syndrome in patients who have had primary surgical and/or radiation therapy for cushing's disease and continue to manifest symptoms and signs of hypercortisolemia.


Eligibility criteria:
inclusion criteria: * are at least 18 years of age. * have a presumptive diagnosis of cushing's disease (cushing's syndrome due to an acth secreting pituitary tumor). * have previously had pituitary surgery and/or pituitary radiation with the intent of curing or treating cushing's disease. * have clinical symptoms and signs of hypercortisolism. * are able to provide written informed consent. * are expected to complete the study. exclusion criteria: * are surgical candidates for pituitary surgery or have had pituitary surgery within 8 weeks before screening. * have taken any medication that may interfere with protocol testing procedures within 30 days of initial screening (phenobarbital, phenytoin, carbamazepine, oxcarabazepine, primidone, rifampin, rifapentine, rifabutin, ethosuximide, pioglitazone, efavirenz, neviparine, modafinil, st. johns wort, glucorticoids, estrogen containing oral contraceptives). * have received investigational treatment (drug, biologic agent or device) within 30 days of screening. * have a non-endogenous source of hypercortisolemia such as factitious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic cushing's syndrome), factitious or therapeutic use of acth. * have pseudo-cushing's syndrome. subjects with suspected pseudo-cushing's syndrome such as those with severe obesity, major depression or a history of alcoholism. * uncontrolled, clinically significant hypothyroidism or hyperthyroidism. * have renal failure as defined by a serum creatinine of 202 mg/dl. * elevated total bilirubin (\>1.5x uln), elevated alt(\>3x uln) or ast (\>3x uln).

Keywords: cushing's disease cushing's syndrome cushings pituitary acth adrenocorticotropic hormone ectopic adrenal adenoma adrenal carcinoma adrenal autonomy cortisol hypercortisolemia cushinoid moon facies dorsalcervical fat plethora hirsutism violaceous striae hormone contraceptive endocrine cushing syndrome ectopic acth secretion
ascending dose study of opc-108459 intravenous infusions in patients with paroxysmal and persistent atrial fibrillation

Conditions: Atrial Fibrillation; Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation

Summary: the purpose of part 1 of this study is to determine the maximally tolerated dose of opc-108459 in patients with paroxysmal and persistent atrial fibrillation (af). the purpose of part 2 of this study is to determine potential efficacy of dose(s) of opc-108459 for the treatment of paroxysmal and persistent atrial fibrillation.

this trial will test the pharmacokinetic and pharmacodynamic characteristics of ascending doses of opc-108459 in separate populations of paroxysmal and persistent af subjects. the trial will consist of two parts. each part will evaluate two populations of subjects presenting for cardioversion in a hospital setting. cohorts of paroxysmal and persistent subjects may have their dose increased independently.

Eligibility criteria:
inclusion criteria: * subjects with paroxysmal atrial fibrillation (af) (recent or new onset) or subjects with persistent af at the time of randomization * subjects who are hemodynamically stable * subjects with a low risk of thromboembolic potential * subjects who are willing to comply with the reproductive precautions exclusion criteria: subjects with: * history of long qt syndrome, torsade de pointes or an uncorrected qt interval of \> 450 ms * history of myocardial infarction within 6 months of screening * acute coronary syndrome, angina or active myocardial ischemia diagnosed by ecg, or other imaging within 6 months of screening * history of ventricular tachycardia, fibrillation, or resuscitated cardiac arrest * history of clinically significant congenital heart disease * presence of severe aortic or mitral stenosis, aortic or mitral regurgitation, atrial septal defect, or other conditions leading to af * diagnosis of heart failure nyha class ii-iv or with an ejection fraction \<40% (part 1 only) * diagnosis of heart failure nyha class iv or nyha i, ii, or iii with an ejection fraction \<35% (part 2 only) * concomitant treatment with class i or iii anti-arrhythmics agents unless the medication was discontinued more than 5 half-lives before dosing * history of seizures * diagnosis of atrial flutter * diagnosis of stroke, tia (transient ischemic attack), or any transient neurological deficit within 1 year of screening or known carotid artery stenosis of \>50% * cardiac surgery within 3 months of screening * bradycardia (\< 50 bpm) or sick sinus syndrome, unless controlled by a pacemaker * current reversible cause of af * wolff-parkinson-white syndrome * any congenital abnormality, severe valve disease * subjects who have taken another investigational product within 30 days of dosing

Keywords: atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation a-fib